Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
Rheumatology (Oxford)
.
2020 Sep 1;59(9):e48-e49.
doi: 10.1093/rheumatology/keaa255.
Authors
Yoshikazu Nakaoka
1
,
Katsuhisa Yamashita
2
,
Shinji Yamakido
3
Affiliations
1
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita.
2
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka.
3
Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.
PMID:
32594147
PMCID:
PMC7449802
DOI:
10.1093/rheumatology/keaa255
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Humans
Remission Induction
Takayasu Arteritis* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
tocilizumab